Abstract:<h3>Importance</h3><p>Positron emission tomography (PET) imaging now allows in vivo visualization of both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau neurofibrillary tangles. Observing their progressive accumulation in the brains of clinically normal older adults is critically important to understand the pathophysiologic cascade leading to AD and to inform the choice of outcome measures in prevention trials.</p><h3>Objective</h3><p>To assess the associations among Aβ, tau, and cognition, measured during different observation periods for 7 years.</p><h3>Design, Setting, and Participants</h3><p>Prospective cohort study conducted between 2010 and 2017 at the Harvard Aging Brain Study, Boston, Massachusetts. The study enrolled 279 clinically normal participants. An additional 90 individuals were approached but declined the study or did not meet the inclusion criteria. In this report, we analyzed data from 60 participants who had multiple Aβ and tau PET observations available on October 31, 2017.</p><h3>Main Outcomes and Measures</h3><p>A median of 3 Pittsburgh compound B–PET (Aβ, 2010-2017) and 2 flortaucipir-PET (tau, 2013-2017) images were collected. We used initial PET and slope data, assessing the rates of change in Aβ and tau, to measure cognitive changes. Cognition was evaluated annually using the Preclinical Alzheimer Cognitive Composite (2010-2017). Annual consensus meetings evaluated progression to mild cognitive impairment.</p><h3>Results</h3><p>Of the 60 participants, 35 were women (58%) and 25 were men (42%); median age at inclusion was 73 years (range, 65-85 years). Seventeen participants (28%) exhibited an initial high Aβ burden. An antecedent rise in Aβ was associated with subsequent changes in tau (1.07 flortaucipir standardized uptake value ratios [SUVr]/PiB-SUVr; 95% CI, 0.13-3.46;<i>P</i> = .02). Tau changes were associated with cognitive changes (−3.28<i>z</i>scores/SUVR; 95% CI, −6.67 to −0.91;<i>P</i> = .001), covarying baseline Aβ and tau. Tau changes were greater in the participants who progressed to mild cognitive impairment (n = 6) than in those who did not (n = 11; 0.05 SUVr per year; 95% CI, 0.03-0.07;<i>P</i> = .001). A serial mediation model demonstrated that the association between initial Aβ and final cognition, measured 7 years later, was mediated by successive changes in Aβ and tau.</p><h3>Conclusions and Relevance</h3><p>We identified sequential changes in normal older adults, from Aβ to tau to cognition, after which the participants with high Aβ with greater tau increase met clinical criteria for mild cognitive impairment. These findings highlight the importance of repeated tau-PET observations to track disease progression and the importance of repeated amyloid-PET observations to detect the earliest AD pathologic changes.</p>

Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model

Alzheimers-associated inflammatory alterations mediate tau-associated neurodegeneration in limbic and temporal regions across clinical variants of Alzheimers disease

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

Microglial Activation and Connectivity in Alzheimer Disease and Aging

The microglial translocator protein (TSPO) in Alzheimer's disease reflects a phagocytic phenotype

Associations between sex, body mass index and the individual microglial response in Alzheimer's disease

Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer's Disease

Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease

Reduction in Constitutively Activated Auditory Brainstem Microglia in Aging and Alzheimer's Disease

Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease

Reduction in Constitutively Activated Auditory Brainstem Microglia in Aging and Alzheimer’s Disease

Relationship between tau, neuroinflammation and atrophy in Alzheimer's disease: The NIMROD study

Microglial responses partially mediate the effect of Aβ on cognition in Alzheimer's disease

In Vivo [18F]SMBT‐1 Imaging of Reactive Astrocytes in Mouse Models of Alzheimer’s Disease ‐ Temporospatial Relationship with Amyloid, Tau and Microgliosis

Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer's disease

Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains

Microglial Reactivity Correlates with Presynaptic Loss Independent of β‐Amyloid and Tau

Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer's Disease

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study